Dercos Anti-Dandruff Treatment Shampoo for Normal to Oily Hair

Clinically Proven Efficacy:

• Up to 100% visible dandruff eliminated on 1st use. (1)
• Clinically-proven action on dandruff & itchy scalp.
• Control of dandruff and reduction of the recurrence.
• Soothing to help relieve the sensation of itchiness associated with dandruff. Pleasant fragrance.
• 2-minute application.

(1) Consumer test on 262 subjects after 2 weeks of regular use – Italy.

Expertise you can trust. Read the scientific publications supporting our dermatological solutions:

• Understanding the Scalp: Dandruff and Seborrheic Dermatitis
  Read More: https://doi.org/10.1177/12034754251368845

Dandruff (DF) and seborrheic dermatitis (SD) are prevalent, chronic scalp disorders that affect a large portion of the global population, often leading to significant psychological distress and quality-of-life impairment. While DF is a milder form characterized by mild scaling, itching, and no visible inflammation, SD presents as a more severe condition with red, scaly, and often inflamed lesions. Despite the high prevalence of these conditions, research specific to their epidemiology and management in Canada remains limited. This review examines the etiology, epidemiology, and management of DF and SD from a Canadian perspective. It highlights the role of Malassezia species in the pathogenesis of both conditions and explores the influence of genetic, environmental, and microbial factors. The review also outlines the diverse clinical presentations of DF and SD across different ethnicities and the effectiveness of various over-the-counter and prescription treatments available. Additionally, the article emphasizes the lack of a Canadian consensus on the management of these conditions, calling for further research and formalized guidelines to better inform health care providers and improve patient care. Given the diverse Canadian population and the increasing burden of DF and SD, a more tailored approach to treatment is essential to address the challenges posed by these chronic conditions.

• A Comparative Randomized Clinical Study Assessing the Efficacy of a 1% Selenium Disulfide-Based Shampoo versus 2% Ketoconazole Shampoo in Subjects with Moderate to Severe Scalp Seborrheic Dermatitis 
  Read More: https://pmc.ncbi.nlm.nih.gov/articles/PMC11627539/

Scalp seborrheic dermatitis (SSD) is a chronic, relapsing, and inflammatory condition impacting quality of life (QoL). This multi-centric, double-blinded, randomized 4-week study evaluated the efficacy of a 1% selenium disulphide-containing shampoo (SeS2 shampoo, Dercos® Anti-Dandruff DS, Vichy Laboratoires) compared to a 2% ketoconazole shampoo in 64 adult subjects with moderate to severe SSD. Both shampoos significantly (p < 0.001) improved SSD severity and total scale score as early as Day 3, with reductions of 71% and 75% respectively for SeS2, and 69% and 68% for ketoconazole, by Day 28. Signs and symptoms, including erythema, irritation, and itching, improved significantly in both groups over the study period, with SeS2 showing an earlier onset of itch relief and quality-of-life improvement. Cosmetic acceptability was rated higher for SeS2 shampoo, and both products were very well tolerated. The study concluded that SeS2 shampoo is a reliable and well-tolerated alternative care to ketoconazole shampoo for managing moderate to severe scalp seborrheic dermatitis.

This study was conducted by an international team of dermatologists, including researchers from the University of Chicago Medicine, State University of Rio de Janeiro, and Ramon y Cajal University Hospital (Madrid), and was funded by Vichy Laboratoires.

Barbosa V, Melo DF, Vañó-Galván S, Lutchmanen-Kolanthan V, Sant'Anna B, Leclerc-Mercier S, Reygagne P. A Comparative Randomized Clinical Study Assessing the Efficacy of a 1% Selenium Disulfide-Based Shampoo versus 2% Ketoconazole Shampoo in Subjects with Moderate to Severe Scalp Seborrheic Dermatitis. Skin Appendage Disord. 2024 Dec;10(6):497–504. doi: 10.1159/000539209. Epub 2024 Jun 18. PMID: 39659649; PMCID: PMC11627539.